
Study shows rising popularity of over-the-counter birth control pill
Two years after U.S. approval of the first over-the-counter birth control pill, new research shows many people who face barriers to medical care are turning to it.
The study, published Monday in JAMA Network Open, included data from 986 people ages 15 to 45 across 44 states. All had obtained the pill -- known as Opill -- either online or from a pharmacy.
Researchers found many switched from less effective birth control methods or from using no contraception at all.
There was a 31.8% increase in use among people who had previously used no birth control, and a 41% increase among those who had relied on methods like condoms or emergency contraception.
Opill, made by drug company Perrigo, is a progestin-only pill that can be bought without a prescription. When the U.S. Food and Drug Administration approved it in 2023, it said the move could help lower barriers to access.
At that time, the FDA noted that nearly half of the 6.1 million pregnancies in the U.S. each year are unintended, CBS News reported.
"This is one of the first studies to show that over-the-counter birth control pills are reaching the very people they're meant to help -- those who face the greatest barriers to care," said lead study author Dr. Maria Rodriguez, a professor of obstetrics and gynecology at Oregon Health & Science University in Portland.
The study found that people using the OTC pill were more often uninsured, younger (15 to 20 years of age), and living in rural areas.
The top reason people gave for choosing the OTC pill was that it did not require a doctor's appointment. Others said they did not have a regular physician.
"At a time when pregnancy is becoming even more dangerous in the United States -- especially for people of color, those with low incomes and those living in rural communities -- our findings underscore that OTC contraception is a powerful tool for reproductive autonomy," Rodriguez said in a news release.
An outside expert who reviewed the findings agreed.
Dr. Jessica Shepherd is a board-certified OB/GYN and chief medical officer of the online health company Hers.
"While greater access to contraception without prescriptions can be life-changing for women with limited resources, it also highlights how deeply the repercussions of unplanned pregnancies still ripple through health care systems and communities," she told CBS News.
"Unplanned pregnancies often result in higher maternal and infant health risks, financial strain and long-term socioeconomic challenges-consequences that weigh most heavily on women who already face barriers to care," Shepherd added.
More information
Learn more about how Opill works.
Copyright © 2025 HealthDay. All rights reserved.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


UPI
4 hours ago
- UPI
Study shows rising popularity of over-the-counter birth control pill
Two years after U.S. approval of the first over-the-counter birth control pill, new research shows many people who face barriers to care are turning to it. File Photo by Billie Jean Shaw/UPI Two years after U.S. approval of the first over-the-counter birth control pill, new research shows many people who face barriers to medical care are turning to it. The study, published Monday in JAMA Network Open, included data from 986 people ages 15 to 45 across 44 states. All had obtained the pill -- known as Opill -- either online or from a pharmacy. Researchers found many switched from less effective birth control methods or from using no contraception at all. There was a 31.8% increase in use among people who had previously used no birth control, and a 41% increase among those who had relied on methods like condoms or emergency contraception. Opill, made by drug company Perrigo, is a progestin-only pill that can be bought without a prescription. When the U.S. Food and Drug Administration approved it in 2023, it said the move could help lower barriers to access. At that time, the FDA noted that nearly half of the 6.1 million pregnancies in the U.S. each year are unintended, CBS News reported. "This is one of the first studies to show that over-the-counter birth control pills are reaching the very people they're meant to help -- those who face the greatest barriers to care," said lead study author Dr. Maria Rodriguez, a professor of obstetrics and gynecology at Oregon Health & Science University in Portland. The study found that people using the OTC pill were more often uninsured, younger (15 to 20 years of age), and living in rural areas. The top reason people gave for choosing the OTC pill was that it did not require a doctor's appointment. Others said they did not have a regular physician. "At a time when pregnancy is becoming even more dangerous in the United States -- especially for people of color, those with low incomes and those living in rural communities -- our findings underscore that OTC contraception is a powerful tool for reproductive autonomy," Rodriguez said in a news release. An outside expert who reviewed the findings agreed. Dr. Jessica Shepherd is a board-certified OB/GYN and chief medical officer of the online health company Hers. "While greater access to contraception without prescriptions can be life-changing for women with limited resources, it also highlights how deeply the repercussions of unplanned pregnancies still ripple through health care systems and communities," she told CBS News. "Unplanned pregnancies often result in higher maternal and infant health risks, financial strain and long-term socioeconomic challenges-consequences that weigh most heavily on women who already face barriers to care," Shepherd added. More information Learn more about how Opill works. Copyright © 2025 HealthDay. All rights reserved.


UPI
6 hours ago
- UPI
21 state AG's ask feds to ban 'designer Xanax' after Kentucky ban
1 of 2 | "This deadly drug has no place in our communities, and now we have the tools needed to get it off the streets and protect more lives," two-term Democratic Gov. Andy Beshear (pictured at the August 2024 DNC in Chicago, Ill.) said Monday. File Photo by Tannen Maury/UPI | License Photo Aug. 19 (UPI) -- Kentucky designated "bromazolam" as a Schedule 1 controlled substance as Gov. Andy Beshear also led a push to have it designated similarly at the federal level. Beshear announced the effort to ban the drug, also known as "designer Xanax" Monday after bromazolam was detected in at least 48 overdose deaths in Kentucky last year. "This deadly drug has no place in our communities, and now we have the tools needed to get it off the streets and protect more lives," the two-term Democratic governor said in a statement. The governor's signature immediately banned the drug from being sold in Kentucky and empowered law enforcement to act and arrest for sales or possession. It also provides further tools for authorities in Beshear's statewide crackdown. A 2021 report suggested that overdose deaths linked to illicit "designer" drugs had surged in the United States a staggering 520% between 2019 and 2020 during the COVID-19 pandemic, according to data from 32 states and the District of Columbia. On Monday, the rumored Democratic presidential candidate pointed to "important progress" in Kentucky's fight against addiction with three straight years of declines in overdose deaths. "And we're committed to ensuring that work continues," Beshear added. Beshear's executive action this week reportedly came following a request by the state's Republican Attorney General Russell Coleman. "We live in a moment when as little as one pill can kill -- and is killing -- our kids," Coleman said Monday in a joint statement with Beshear. "I'm glad we could work together to tackle this grave threat," he added on the bipartisan effort to rid the streets of the "designer" bromazolam. In 1985 the federal government enacted its ban on the so-called "designer drug" Ecstasy entirely due to the fact it was created by chemists and Ecstasy spin-offs were starting to hit the streets. Coleman and 20 other GOP state attorneys general are now calling on the federal government to follow state actions. "Despite its clear dangers, bromazolam remains unscheduled at the federal level, creating significant challenges for law enforcement and public health officials trying to respond to this emerging crisis," read a letter in part to DEA Administrator Terry Cole signed by Coleman and Alabama's Attorney General Steve Marshall, Tim Griffin in Arkansas, Florida's James Uthmeier, Georgia Attorney General Chris Carr, Indiana's Attorney General Todd Rokita and Brenna Bird from Iowa, Liz Murrill of Louisiana, Lynn Fitch of Mississippi, Montana's Austin Knudsen, Mike Hilgers of Nebraska, Drew Wrigley of North Dakota, Dave Yost of Ohio, Oklahoma's Gentner Drummond, Pennsylvania's new Attorney General Dave Sunday, Alan Wilson of South Carolina, Marty Jackley of South Dakota, Jonathan Skrmetti of Tennessee, Virgina's Jason Miyares, John 'JB' McCuskey of West Virginia and Ken Paxton of Texas. Coleman's letter pointed to how the originally synthesized but never approved for medical use bromazolam is now being illegally sold on the streets and in online platforms. The band of Republican state chief law enforcement officers argues that without its scheduling on a federal level, bromazolam will continue to "evade traditional regulatory and prosecutorial tools," which they added will hinder interdiction efforts and enable "continued distribution through illicit channels." "Virginia took proactive action by scheduling bromazolam," Virginia's Attorney General Jason Miyares said Monday. "Now, I'm encouraging federal action to ensure every state has the same tools to protect Americans," the Republican AG and first Latino elected to statewide office in Virginia posted on social media.


UPI
11 hours ago
- UPI
Del Toro's 'Frankenstein' gets theatrical and Netflix release dates
1 of 5 | Oscar Isaac's "Frankenstein" is set to open in theaters on Oct. 17 and will premiere on Netflix Nov. 7. File Photo by Jim Ruymen/UPI | License Photo Aug. 19 (UPI) -- Oscar-winning filmmaker Guillermo Del Toro's Frankenstein is set for theatrical release on Oct. 17. The horror movie will then premiere on Netflix Nov. 7. The cast includes Oscar Isaac, Jacob Elordi, Mia Goth and Christoph Waltz. The film is an adaptation of Mary Shelley's classic 1818 tale about Victor Frankenstein, "a brilliant but egotistical scientist who brings a creature to life in a monstrous experiment that ultimately leads to the undoing of both the creator and his tragic creation," the streaming service said in a synopsis. FRANKENSTEIN, a film by Guillermo del Toro Starring Oscar Isaac, Jacob Elordi, Mia Goth, and Christoph Waltz. Coming to select theaters October 17 and on Netflix November 7. Netflix (@netflix) August 18, 2025